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manchester.ac.ukAbstractMeta-analysis has shown a modest improvement in first-year growth response to recombinant human GH (r-hGH)
for carriers of the exon 3-deleted GH receptor (GHRd3) polymorphism but with significant interstudy variability.
The associations between GHRd3 and growth response to r-hGH over 3 years in relation to severity of GH deficiency (GHD)
were investigated in patients from 14 countries. Treatment-naı¨ve pre-pubertal children with GHD were enrolled from
the PREDICT studies (NCT00256126 and NCT00699855), categorized by peak GH level (peak GH) during provocation test:
%4 mg/l (severe GHD; nZ45) andO4 to!10 mg/l mild GHD; nZ49) and genotyped for the GHRd3 polymorphism (full length
(fl/fl, fl/d3, d3/d3). Gene expression (GE) profiles were characterized at baseline. Changes in growth (height (cm) and SDS)
over 3 years were measured. There was a dichotomous influence of GHRd3 polymorphism on response to r-hGH, dependent
on peak GH level. GH peak level (higher vs lower) and GHRd3 (fl/fl vs d3 carriers) combined status was associated with
height change over 3 years (P!0.05). GHRd3 carriers with lower peak GH had lower growth than subjects with fl/fl
(median difference after 3 years K3.3 cm;K0.3 SDS). Conversely, GHRd3 carriers with higher peak GH had better growth
(C2.7 cm;C0.2 SDS). Similar patterns were observed for GH-dependent biomarkers. GE profiles were significantly different
between the groups, indicating that the interaction between GH status and GHRd3 carriage can be identified at a
transcriptomic level. This study demonstrates that responses to r-hGH depend on the interaction between GHD severity
and GHRd3 carriage.ice
.0 UEuropean Journal of
Endocrinology
(2015) 173, 777–789IntroductionResponse to growth hormone (GH) therapy is variable in
subjects who are GH-deficient (1). Factors including age,
BMI, and gender have a role in this individual variability,
while genetic factors influencing response to GH areactively being investigated. Dos Santos et al. (2) showed
that the exon 3-deleted GH receptor (GHRd3) was
associated with better growth response to recombinant
human GH (r-hGH) treatment in children with idiopathicnsed under a Creative Commons
nported License.
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173 :6 778short stature and children born small for gestational age
(SGA). This initial observation was confirmed in patients
with Turner syndrome (3), GH deficiency (GHD) (4, 5),
those born SGA (6), and those with idiopathic short
stature (7). However, several independent studies did not
detect such associations (8, 9, 10, 11, 12, 13, 14, 15).
Confounding factors, such as severity of GHD, may
explain conflicting data between studies.
With the aim of clarifying this controversy, we
analyzed the clinical and genetic data generated in the
PREDICT and the PREDICT long-term follow-up studies
(ClinicalTrials.gov Identifiers: NCT00256126 and
NCT00699855) (16). In this observational study, 94
subjects with GHD (45 classified as having severe GHD
and 49 as having mild GHD) were followed-up during 3
years of r-hGH therapy. Auxological measurements were
taken every year, and change in growth relative to baseline
was used tomeasure the effect of the therapy and tested for
association with the GHRd3 polymorphism. Changes in
serum biomarkers were measured after 1 month of r-hGH
therapy and were also tested for association with the
GHRd3 polymorphism. In all analyses, the effect of
GHRd3 carriage in relation to GHD severity was assessed.
In order to identify potential mechanisms at the cellular
level associated with this interaction, baseline gene
expression (GE) profiles were analyzed.Table 1 Clinical characteristics at baseline for the GHD groups.
Variablea Any GHD
n 94
Female gender (n) 31
Age (years) 9.0 (0.3)
Height SDS K2.3 (0.1)
Weight SDS K1.4 (0.1)
Bone age (years) 6.8 (0.3)
Distance to target height SDS K1.4 (0.2)
IGF1 SDS K1.8 (0.1)b
IGFBP-3 SDS K0.3 (0.1)b
Glucose (mmol/l) 4.8 (0.1)
HOMA-IR 1.1 (0.1)
Insulin (pmol/l) 38.2 (3.0)
Total cholesterol (mmol/l) 4.8 (0.1)
HDL-cholesterol (mmol/l) 1.7 (0.0)
LDL-cholesterol (mmol/l) 2.7 (0.1)
Triglycerides (mmol/l) 0.8 (0.0)
Free T4 (pmol/l) 15.1 (0.2)
TSH (mIU/l) 2.5 (0.2)
HOMA-IR, homeostatic model assessment insulin resistance; IGFBP-3, insulin-
T4, thyroxine; TSH, thyroid-stimulating hormone.
aFor continuous variables, the means (standard error of the mean) are shown fo
(severe: peak GH %4 mg/l, mild: peak GH O4 to !10 mg/l). The indicated P va
All baseline blood samples were taken under fasted conditions.
bnZ92.
cnZ43.
dnZ49.
www.eje-online.orgMaterials and methods
Study design
The PREDICT Long-Term Follow-up of Predictive Markers
study is an open-label, multicenter study in subjects with
GHD. Inclusion criteria included: i) subjects who had
completed the PREDICT study assessment of serum
biomarkers over 1 month of r-hGH treatment) and who
had been followed-up for at least 1 year after completion
of the PREDICT study, while still on r-hGH therapy and
ii) parental or guardian written informed consent, given
before any data collection. Subjects on an investigational
drug or participating in another interventional clinical
trial since completion of the PREDICT trial were not
included. The analyses were restricted further to subjects
with GHDwho had participated in all 3 years of follow-up.
Data on 94 subjects with GHD, from the per-protocol
population, were evaluated (see baseline characteristics in
Table 1). All patients were prepubertal at enrolment, with
52% remaining prepubertal at year 2 and 41%at year 3. The
diagnosis of GHD was based on two different stimulation
tests both with a peak GH value!10 mg/l. The stimulation
tests and GH assay used were chosen by the local centre.
The most common tests used were: Insulin tolerance test,
arginine and clonidine. The combined growth hormone-
releasing hormone-arginine test was not used. PatientsSevere GHD Mild GHD P value
45 49 –
14 17 –
8.9 (0.4) 9.2 (0.4) 0.6801
K2.5 (0.2) K2.2 (0.1) 0.2844
K1.2 (0.2) K1.5 (0.1) 0.3719
6.7 (0.5) 7.0 (0.5) 0.6374
K1.4 (0.3) K1.3 (0.2) 0.7593
K1.8 (0.2)c K1.7 (0.2)d 0.5278
K0.4 (0.2)c K0.2 (0.1)d 0.3455
4.7 (0.1) 4.8 (0.1) 0.4430
1.3 (0.7) 1.0 (0.1) 0.0766
43.3 (4.4) 32.7 (4.0) 0.0785
4.7 (0.1) 4.9 (0.1) 0.2700
1.6 (0.1) 1.8 (0.1) 0.0556
2.7 (0.1) 2.8 (0.1) 0.6072
0.9 (0.1) 0.7 (0.1) 0.1679
15.0 (0.3) 15.3 (0.3) 0.5174
2.5 (0.2) 2.6 (0.3) 0.8378
like growth factor binding protein-3; IGF1, insulin-like growth factor 1;
r all GHD subjects (irrespective of GHD severity) and for GHD severity groups
lues were obtained from a Student’s t test between mild and severe GHD.
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used in the local units, in order to capture the full range of
GHD patients currently being treated with r-hGH. Patients
with GHD associated with etiologies such as CNS tumors
with or without cranial irradiation were excluded. GHD
was further classified by GH peak during GH stimulation
testing as severe (GH peak %4 mg/l) or mild (GH peak O4
to !10 mg/l), based on the highest peak level in two
independent stimulation tests. Serum biomarkers col-
lected at baseline and after 1 month in NCT00256126
were assayed in a central laboratory (qLAB, Livingston,
Edinburgh, UK) (17). Serum insulin-like growth factor1
(IGF1) and insulin-like growth factor-binding protein 3
(IGFBP3) levels were measured using chemiluminescent
immunoassays (DPC Immulite 2000: Siemens, Healthcare
Diagnostics, Norwood,MA, USA). Levels were converted to
SDS using relevant reference data (18). Other parameters
(thyroxine (T4), thyroid-stimulating hormone (TSH),
lipids, insulin and glucose) were measured in standard
assays at the central laboratory.
Themajority of patients had isolated GHD. Three (3%)
were receiving hydrocortisone replacement treatment,
and 9 (10%) were on T4 (evenly distributed between GHD
severity groups). Molecular genetic studies to define the
etiology of the GHD and MR scanning of the hypo-
thalamic–pituitary axis were not required as part of the
protocol.
Growth parameters were collected at baseline and on
an annual basis. All were converted to SDS using the
Sempe´ reference data (19).
During years 1, 2, and 3, subjects with severe GHD
were treated withmedian GH doses of 34, 31, and 31 mg/kg
per day, respectively, and subjects with mild GHD were
treated with median doses of 35, 34, and 34 mg/kg per day
respectively. There was no significant difference across the
years of therapy in the dose received by children with mild
GHD (rank sum PZ0.98) or in the dose received by those
with severe GHD (rank sum PZ0.30).
We have previously demonstrated no confounding
effects of country of origin or population stratification on
the response to r-hGH after the first year of treatment (17).Genotyping assay
The genotyping of the two GHR exon 3 alleles (d3, exon 3
deletion; fl, full-length gene) was carried out using a
gel-based triplex PCR technique published by Pantel et al.
(20) All DNA samples were successfully genotyped and no
deviation from the Hardy–Weinberg equilibrium (Fisher’s
exact test PO5%) was observed. No imbalance in genotypefrequencies was found between subjects with mild and
severe GHD (Fisher’s exact test PZ0.79). The numbers of
d3/d3 homozygotes was small compared to d3/fl hetero-
zygotes (Supplementary Table 1, see section on supple-
mentary data given at the end of this article), therefore no
further statistical analysis of genotype was performed.
Subsequent to the determination of the GHR exon 3
alleles, genetic data were encoded as presence or absence
of the d3 allele (d3 carriers, fl/fl).Statistical analysis
Time series analyses " Change over time in growth-
related endpoints was tested using linear mixed-effect
models (to model change in endpoints over 3 years of
therapy). The interaction between GHRd3 polymorphism
and GHD severity was modeled as a fixed effect and inter-
individual variability as a random effect. These models are
referred to as conditional models. Additive models, to test
GHRd3 polymorphism and disease severity without
interaction, were also used. For all models, gender was
included as a covariate. The significance of each term (for
all models) was tested using ANOVA type III. Levels in the
variables were encoded as follows: GHD severity term
(severe; mild); GHRd3 polymorphism (d3 carriers; fl/fl);
and gender (female; male). In addition, an analysis of the
impact of the GHRd3 polymorphism-GHD severity
interaction on growth stratified by both country of
origin of the patient and the study site was undertaken
(data not shown).
Change in serum biomarker levels " Changes in bio-
marker levels after 1 month of therapy were assessed using
linear models. The interaction between GHRd3 poly-
morphism and disease severity was tested with interaction
models, while the effect from both terms (in the absence of
interaction) was tested with additive models. All models
included age at baseline and gender as covariates. The
significance of each termwas tested using ANOVA type III.
P values were adjusted using the Benjamini–Hochberg
correction. Levels in the variables were encoded as
previously described.
Transcriptome analysis " In order to explore possible
mechanisms related to the GHRd3-GHD severity associ-
ation, GE profiling was performed at baseline on whole
blood RNA extracted centrally by qLAB using the PAXgene
96 blood RNA kit (Qiagen). Reduction of globin messenger
RNA was undertaken using the Ambion GLOBIN Clear
Human kit (Life Technologies, Paisley, UK). Comp-
lementary RNA was generated using the Two-Cyclewww.eje-online.org
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173 :6 780Eukaryotic Target Labelling kit (Affymetrix, Santa Clara,
CA, USA) before hybridization to Affymetrix GeneChip
Human Genome U133 Plus 2.0 Arrays.
Processing and normalization of GE data from each
patient were performed using a RobustMulti-array Average
background correction modified for probe sequence with
quantile normalization and median polish (Partek
Genomics Suite, version 6.3, St Louis, MO, USA). Con-
founding effects due to variations in cell populations and
outliers were examined by cross validation using principal
component analysis and iso-map multidimensional scal-
ing (Qlucore Omics Explorer 2.2, Qlucore, Lund, Sweden).
The relationships between basal GE and GHD severity
and basal GE and carriage of the GHRd3 polymorphism
were assessed using rank regression and ANOVA as
appropriate, adjusting for gender, ethnicity, age and
baseline BMI as potential confounding factors (Qlucore
Omics Explorer 2.2).
Causal network analysis of transcriptomic data " Cau-
sal network analysis (CNA) allows the identification and
prioritisation of regulatory system elements within tran-
scriptomic models. CNA was performed within Ingenuity
Pathways Analysis (IPA, Redwood City, CA, USA) using the
overlap of associated GE between GHD severity and
carriage of the GHRd3 polymorphism.
CNA identifies upstream molecules up to three steps
distant that control the expression of the genes in the
dataset, and thus provides insight into information flow
within the network (21). These relationships are derived
from published literature and multiple database platforms
curated in the Ingenuity Knowledge Base. A prediction of
the activation state for each regulatory factor (master
regulator), based on the direction of change, was
calculated (z-score) using the GE patterns of the transcrip-
tion factor and its downstream genes. An absolute z-score
ofRj1.4j and a false discovery rate (FDR) corrected P value
!0.05 (Fisher’s Exact test with Benjamini Hochberg
correction) were used to compare the regulators identified
in each of the four GE datasets (severe GHD:fl/flGHR/
severe GHD:GHRd3 carriage/mild GHD: fl/flGHR/mild
GHD:GHRd3 carriage) using hierarchical clustering (Eucli-
dean metric).
Baseline GE and GH signaling " The predicted effect of
basal GE in each of the four GHR genotype:GH status
categories (severe GHD:fl/flGHR/severe GHD:GHRd3
carriage/mild GHD: fl/flGHR/mild GHD:GHRd3 carriage)
on the activity of the genes for each of themolecules in thewww.eje-online.orgGH signalling pathways was determined using the
Molecular Activity Prediction (MAP) tool in IPA.
Clinical Trial registration " Clinical trials registration
numbers: NCT00256126 and NCT00699855. Classi-
fication: Growth hormone basic.Results
Baseline characteristics
The study included 94 subjects with GHD (mild GHD,
nZ49; severe GHD, nZ45; see Materials and methods for
definition) with a 3-year follow-up. No significant
differences were observed in baseline characteristics
between the GHD groups (Table 1). Frequency of the
GHR exon 3 deletion (d3 allele) was 36% for the mild GHD
group and 36% for the severe GHD group. These
frequencies are consistent with previous observations
(2, 20). No significant differences in baseline character-
istics were found between subjects with the fl/fl genotype
and d3 carriers when assessed by GHD severity group
(Supplementary Table 1).Growth response related to GHRd3 polymorphism
carriage and GHD severity
The impact of GHRd3 on change in height (cm) and
change in height SDS during 3 years of GH treatment was
tested (Fig. 1). When considering all subjects with GHD
participating in this study (irrespective of their GHD
severity), no significant association between GHRd3
polymorphism and growth response was found.
However, the relationship between the GHRd3 poly-
morphism and GH-dependent growth response variables
was significantly influenced by the severity of GHD.
Modeling change in height (cm) over time (using a linear
mixed-effect framework) revealed a significant effect from
the interaction between GHRd3 polymorphism and GHD
severity (interaction PZ0.0018; Fig. 1). In the group with
severe GHD, d3 carriers had a significantly lower growth
response compared with subjects having a full-length
(fl/fl) GHR (differences in medians were K1.0, K2.6, and
K3.3 cm for years 1, 2, and 3, respectively; Table 2).
Conversely, in the group with mild GHD, d3 carriers had a
higher growth response than subjects with fl/fl (differences
in medians were C1.2,C2.0, and C2.7 cm for years 1, 2,
and 3, respectively). An identical pattern was found for
change in height SDS (interaction PZ0.010; Fig. 1) and for
height velocity SDS (interaction PZ0.027). Age and r-hGH
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Figure 1
Change from baseline in height over time. Top panels show
change in height (cm) and bottom panels show change in
height SDS. Lines correspond to mean and error bars show the
standard error of the mean. The interaction between GHRd3
polymorphism and GHD severity was significant for both
endpoints (PZ0.0018 and 0.010, respectively, for change in cm
and SDS). GHD, growth hormone deficiency.
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(data not shown). The country of origin and the study
site also had no influence on the impact of the GHRd3
polymorphism-GHD severity interaction on growth
responses (data not shown).Table 2 Change in height from baseline: median and 95% bootst
Endpoint Severity Year
fl/fl (
Change in height (cm) Mild GHD 1 7.1
2 14.1
3 21.0
Severe GHD 1 8.8
2 16.5
3 24.1
Change in height SDS Mild GHD 1 0.4
2 0.6
3 0.8
Severe GHD 1 0.6
2 1.2
3 1.4
GHD, growth hormone deficiency; r-hGH, recombinant human growth hormonThe significant interaction between GHRd3 poly-
morphism and GHD severity was not specific to the
chosen statistical methodology, as all findings were
confirmed with alternative approaches (non-parametric
models). Furthermore, compared with a peak GH level
cut-off of 4 mg/l to classify severity, the difference in height
change between GHRd3 carriers and subjects with fl/fl
with severe GHD was intensified when using a more
stringent severity cut-off of 2 mg/l. Differences between
GHRd3 vs fl/fl carriage at year 1 were K4.7 cm for height
andK0.6 for height SDS.
The possible association of GHRd3 polymorphism
and GHD severity with weight-related parameters, such as
annualized BMI SDS and annualized weight SDS, was
also tested. The GHRd3 polymorphism–GHD severity
interaction was not significant for BMI (PZ0.22) and
only marginal for weight (PZ0.059).Change in serum biomarkers after 1 month of therapy
The impact of 1 month of r-hGH treatment on the
circulating concentrations of selected biomarkers (IGF1,
IGFBP3, TSH, free T4, fasting glucose, insulin, cholesterol
(HDL, LDL, and triglycerides) was investigated. Results
from linear models are summarized in Table 3. As for
growth response markers, a significant GHRd3 poly-
morphism–GHD severity interaction (FDR !5%) was
found at 1 month for changes in IGF1 SDS, triglycerides,
LDL-cholesterol, and free T4 levels (Fig. 2). A marginal
interaction (FDRZ13%) was found for change in fasting
insulin levels. Regarding glucose–insulin metabolism, in
subjects with severe GHD, fl/fl and d3 carriers did not differ
in terms of changes in fasting insulin or homeostatic
model assessment of insulin resistance (HOMA-IR).rap CI estimates for each year of r-hGH therapy.
median and
95% CI)
d3 carriers (median
and 95% CI)
Difference
(d3 carriers – fl/fl)
(6.6; 8.2) 8.3 (7.4; 8.6) 1.2
(13.2; 15.0) 16.1 (14.3; 16.5) 2.0
(19.7; 21.4) 23.7 (21.5; 24.0) 2.7
(8.0; 10.2) 7.8 (7.0; 9.3) K1.0
(14.5; 19.2) 13.9 (13.0; 15.9) K2.6
(21.7; 26.4) 20.8 (19.6; 23.6) K3.3
(0.3; 0.6) 0.5 (0.3; 0.7) 0.1
(0.3; 0.8) 0.8 (0.5; 1.0) 0.2
(0.5; 1.0) 1.0 (0.9; 1.2) 0.2
(0.6; 0.8) 0.5 (0.4; 0.7) K0.1
(0.8; 1.2) 0.7 (0.4; 0.9) K0.5
(1.1; 1.6) 1.1 (0.6; 1.3) K0.3
e.
www.eje-online.org
Table 3 Change or percentage change in serum biomarker
levels after 1 month of r-hGH therapy.
Biomarkera FDR
Mild GHD
(difference,
d3 carriers –
fl/fl)b
Severe GHD
(difference,
d3 carriers –
fl/fl)b
Triglycerides (mmol/l)c 0.0119 29.4 K21.0
Free T4 (pmol/l)
c 0.0119 K7.7 9.0
LDL-cholesterol (mmol/l)c 0.0138 K1.1 11.1
IGF1 SDS 0.0138 0.5 K0.3
Total cholesterol (mmol/l)c 0.0564 1.8 6.6
Insulin (pmol/l)c 0.1354 60.0 K35.9
IGFBP-3 SDS 0.2591 0.1 0.0
HDL-cholesterol (mmol/l)c 0.2591 K3.8 7.9
Glucose (mmol/l)c 0.2591 4.4 K8.1
HOMA-IRc 0.2591 66.3 K28.3
Change in IGF1 SDS/
IGFBP-3 SDS
0.3560 K0.3 K0.3
TSH (mIU/l)c 0.3560 K6.5 1.2
FDR, false discovery rate; HOMA-IR, homeostatic model assessment of
insulin resistance; IGFBP-3, insulin-like growth factor binding protein-3;
IGF1, insulin-like growth factor 1; T4, thyroxine; TSH, thyroid-stimulating
hormone.
aParameters are ranked by FDR, which corresponds to the interaction
between GHRd3 polymorphism and GHD severity P value from a linear
model adjusting for age at baseline and gender.
bDifferences between the median value for subjects with the fl/fl genotype
and the median value for d3 carriers are given for mild and severe GHD
separately.
cPercentage change. Units of measurement are given in brackets.
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173 :6 782In contrast, in subjects with mild GHD, significant
differences were found: d3 carriers had aC60% insulin
increase (rank sum PZ0.03) and aC66% HOMA-IR
increase (rank sum PZ0.07) compared with those who
were fl/fl.
Overall, these biomarker patterns were consistent with
those described for growth response markers; that is,
subjectswith severeGHDwhowere fl/fl (with the exception
of insulin and HOMA-IR) and those with mild GHD who
were d3 carriers had larger GH-dependent effects.Relationships between change in IGF1 SDS and change
in height SDS
The impact of the GHRd3 polymorphism–GHD severity
interaction on the relationship between height SDS and
IGF1 SDS was investigated. When considering the whole
GHD population, irrespective of their GHD severity or
GHRd3 classification, change in height SDS after 1 year of
therapy was associated with change in IGF1 SDS after 1
month of therapy (PZ0.013). When the GHRd3 poly-
morphism–GHD severity interaction term was added into
the model, both change in height SDS and the interaction
term were significantly associated with change in IGF1
SDS (height SDS PZ0.046 and interaction term PZ0.023).www.eje-online.orgWhen results were analyzed separately for each
GHD severity and GHRd3 category, a much stronger
relationship between height SDS and IGF1 SDS in subjects
with severe GHD than in those with mild GHD was
observed (Fig. 3). The correlation between IGF1 and height
change was strongest for subjects with severe GHD who
were fl/fl (rZ0.75 with 95% (CI: 0.41; 0.91), PZ0.0008),
and was weaker for those who were d3 carriers (rZ0.35
with 95% CI (K0.05; 0.65), PZ0.089).The correlation for
those with mild GHD, irrespective of GHRd3 status, was
not significant (PO5%; Fig. 3).Relationship between baseline GE, GHD severity
and GHRd3 carriage
The expression of 283 genes was significantly different
between mild and severe GHD (rank regression, P!0.01).
The expression of 457 genes was significantly different in
those carrying a GHRd3 allele and those homozygous for
fl:fl GHR (ANOVA, P!0.01) (Supplementary Table 2, see
section on supplementary data given at the end of this
article). The expression of nine genes overlapped between
these two relationships (P!0.05, Supplementary Table 2),
associated with cellular growth and proliferation
pathways (P!1.0!10K5).
The expression of the GHR gene within the tran-
scriptome data set was determined in relation to GHD
severity and GHR genotype. This analysis demonstrated
lower GHR expression in D3 homozygotes compared to
the fl/fl and fl/d3 genotypes in severe GHD (P!0.05). This
was not significant in mild GHD (Fig. 4A).Causal network modelling of GHRd3 carriage
associated GE
The gene probe sets that overlapped between each pair:
i) severe GHD:fl/flGHR; ii) mild GHD: fl/flGHR; iii) mild
GHD:GHRd3 carriage; iv) severe GHD:GHRd3 carriage)
were identified (Fig. 4B and Supplementary Table 2). CNA
was then used to identify the regulators of the pathways
represented in the overlapping GE profiles in the four
groups (Fig. 4C). There was a predominance of pathways
related to cell growth, cell cycle, cell differentiation and
intracellular signalling. The regulators were ordered by
hierarchical clustering (Fig. 4C), and this demonstrated
that the ‘master’ regulator genes in each of the four groups
were different, although the pathways being controlled
often had a similar function. This indicated that the
interaction between GHRd3 carriage and GHD severity has
a distinct impact on GE. In the group with highest growth
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Figure 2
Change in serum biomarkers after 1 month of r-hGH therapy.
Panels from top left to bottom right correspond to boxplots for
change in IGF1 SDS, percentage change in fasting triglycerides
(unit of measurement: mmol/l), percentage change in free T4
(pmol/l), and percentage change in fasting LDL-cholesterol
(mmol/l). All interaction GHRd3 polymorphism–GHD severity
terms were significantly associated with biomarker changes
(FDR!5%). GHD, growth hormone deficiency; IGF1, insulin-like
growth factor-I; T4, thyroxine.
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173 :6 783response (severe GHD:fl/fl GHR), ACTN2 (a cytoskeleton
protein) was the regulator with the highest activity and
BMP2 (an inducer of bone and cartilage formation) the
lowest, while in the group with the poorest response (mild
GHD:fl/fl GHR), SIN3A (a transcriptional regulator) was
the regulator with the highest activity and IKK (an
activator of NFkB) the lowest.Baseline GE and GH signaling
In order to assess whether the GE profiles associated with
each of the four GHR genotype:GH status groups, the
predicted effect on GH signalling molecules was quanti-
fied. This demonstrated significant differences in activity
in the various GH pathways (Fig. 5). GH status had
different impacts on signalling pathways dependent on
GHR genotype (panel A vs B –fl/fl GHR: those with severe
GHD are predicted to have an activated STAT5 pathway,
and panel C vs D – GHRd3: those with severe GHDare predicted to have inhibition in the ERK pathway).
When comparing between genotypes for both severe and
mild GHD, those carrying GHRd3 have active Stat 1 and
3 pathways compared to inhibition for those with
full-length GHR.Discussion
In the present study, the effect of r-hGH treatment on
growth (over 3 years) and serum biomarker changes (at 1
month) in prepubertal children with GHD was investi-
gated. It was found that treatment efficacy is influenced by
GHRd3 polymorphism but modulated by GHD severity.
The cohort was recruited from growth centers across the
world, and purposely included children whose diagnosis
of GHD was based on local criteria along with a peak
GH level !10 mg/l in two stimulation tests. The cohort
therefore included a wide range of GHD phenotypes from
those with very severe GHD (the lowest peak GH levelwww.eje-online.org
Change in height SDS after 1 year
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Correlation between change in IGF1 SDS and change in height
SDS. Correlation is stratified by GHD severity–GHRd3 poly-
morphism groups. The line was fitted by a linear model, and the
corresponding equation including R2 value is indicated in each
panel. GHD, growth hormone deficiency; IGF1, insulin-like
growth factor 1.
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173 :6 784being 1 mg/l) to those with very mild GHD (the highest
peak GH level being 9 mg/l). Some of the latter would be
likely to retest as having normal GH status at the end of
r-hGH treatment. We consider that having such a wide
range of GH status provides strength to the study as i) it is
reflection of current practice across many centers and ii) it
provides an opportunity to test the full extent of the
interaction between GHRd3 carriage and GH status. GH
levels were assayed in the local centers using their
preferred methodology. In the context of this study, it
was not considered feasible to undertake a central assaying
process for GH. If a single assay had been used, it is possible
that some patients would be allocated to a different level of
GHD severity. However, this would be most unlikely to be
a systematic error and the observations in this study are
consistent across all end-points assessed. For subjects with
mild GHD, d3 carriers had a better growth response than
those with the fl/fl genotype, in support of those studies
that have previously reported the positive impact of
GHRd3 carriage on growth during GH therapy (22). This
positive impact had been described in a range of growth
disorders including GHD, Turner syndrome, short SGAwww.eje-online.orgchildren and those with idiopathic short stature. The GHD
studies had included children with a range of severity of
GHD, but all were retrospective and an interaction
between GHRd3 genotype and GH status was not
examined in detail. The new finding in this study, and
contrary to previous observations, is that subjects with
severe GHD, who were homozygous for the full-length
GHR (fl/fl) had a significantly better growth response than
d3 carriers. The observed differences in r-hGH response
were consistent over the 3 years of follow-up and are
supported by similar findings for changes in IGF1 levels
after 1 month of therapy. This observed interaction
between GHD severity and GHRd3 polymorphisms is not
explained by the administered r-hGH dose. In this study, a
child was considered to have severe GHD if the peak GH
response observed during their GH stimulation test was
%4 mg/l. Importantly, our findings were reproduced when
using a more stringent threshold (at a peak GH of
%2 mg/l), which demonstrates that the observed GHRd3
polymorphism–GHD severity interaction is not depen-
dent on a specific peak GH threshold. In fact, the
difference in height change in subjects with severe GHD
between GHRd3 carriers and those with the fl/fl genotype
was intensified when a more stringent severity threshold
was used. In addition, the effect of the interaction was not
influenced by country of origin of the recruits, nor by the
study site location. Notably the GHRd3 polymorphism
and the severity of GHD had no major impact on any
growth parameter at baseline (Table 1), indicating that the
interaction between GHRd3 and GHD severity is only
unveiled by r-hGH treatment.
The limitation of using local criteria for the diagnosis
of GHD is that different provocation tests, GH assays and
reference preparations will have been used. Therefore the
peak GH values in some cases may not be directly
comparable between subjects. As we have used cut-off
values of 4 mg/l and 2 mg/l to distinguish between severe
andmild GHD, then it is possible that some patients could
be incorrectly allocated to one or other group. This may be
the case, but it would be expected that this would be a
random not a systematic error. In addition, we propose
that the following features of the GHD group provide
validity for using a cut-off level to define severity and
indicate that bias has not been introduced: i) the expected
negative relationship between growth response and peak
GH value is seen in all 3 years of GH treatment;
ii) consistent with the growth response, changes in IGF1
and IGFBP-3 SDS over the first month of GH treatment
were negatively related to peak GH; iii) all the growth and
metabolic endpoints showed consistent responses by
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Figure 4
Gene expression associated with GHD severity and carriage of
the GHRd3 variant. (A) Box and whisker plots of GHR expression
by genotype (median and quartiles of Affymetrix probe-set
205498_at expression) (B) Diagram showing overlap of associ-
ated gene expression with severe compared to mild GHD and
carriage of full length GHR compared to carriage of GHRd3
(P!0.05, numbers represent associated gene probe sets).
(C) CNA was used to define master regulators associated with
the regulation of the overlapping gene expression defined in
(B) (modified P value !0.05 and z-score of activity Oj1.4j).
Data represented as a heat map with hierarchical clustering
(Euclidean metric); biological pathways associated with master
regulators are shown. The colour coding represents the
predicted level of activity of the master regulator – deeper red
represents increasing up-regulation (e.g. ACNT2) and deeper
green represents increased down-regulation (e.g. BMP2).
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173 :6 785severity of GHD and genotype (Tables 2 and 3); iv) using a
more stringent cut-off of %2 mg/l to define severe GHD
strengthened the observations; v) the GHR genotypes have
been shown to be evenly distributed between the severity
categories; vi) as indicated above, the study site had no
effect on the analysis; and vii) analysis of the transcrip-
tomic data supported the existence of an interaction
between GHD severity and GHR genotype.
The significant interaction between GHR isoforms and
GHD severity raises the possibility that genotype and GH
level could influence the total number of GHRs expressed
on a cell and/or efficiency of GH signaling and/or alter theactivity in cellular pathways related to GH responsiveness.
To explore the latter possibility, we used baseline GE
profiling from whole blood to assess whether GHRd3
carriage and GH status could alter GE. Transcriptomic data
from whole blood has been previously shown to be an
effective model to study GH action (23) and human
growth (24). First we examined the relationship between
GHR genotype and GHD severity (Fig. 4A), and showed
that GHR mRNA levels were significantly lower in d3
homozygotes in those with severe GHD. Serum GH
binding protein (GHBP) is derived from the proteolysis
of GHR and, consistent with our observation in severewww.eje-online.org
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Predicted activation
Leads to activation
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Effect not predicted
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Prediction legend
Figure 5
Predicted activity within the GH signal transduction pathways
based on baseline gene expression. Each panel shows the
signalling molecules in the GH pathways. The predicted level of
expression (Orange, increased; Blue, decreased) of each of these
molecules for each of the four GHRd3/GH status groups
(FL-GHR-Severe GHD (38 genes), FL GHR-Mild GHD (64 genes),
GHRd3-Mild GHD (48 genes), GHRd3-Severe GHD (20 genes)) is
shown. The predicted levels of expression in the GH pathway
are derived from the impact of the levels of baseline gene
expression in each of the four states and their direct network
interactions with the GH pathway. First year height velocity
(cm/year) in each of the four states is shown in the left margin of
each panel. The predicted action on the GH pathway molecules
was determined using Molecular Activity Prediction (MAP) tool
in IPA (see Legend below). The principal difference between GH
deficient states for those with full-length GHR (top two panels)
is that those with severe GHD are predicted to have an activated
STAT5 pathway in the basal state. For carriage of GHRd3 (lower
two panels), those with severe GHD are predicted to have
inhibition in the ERK pathway in the basal state. When
comparing between genotypes for both severe and mild GHD,
those carrying GHRd3 have active STAT 1 and 3 pathways
compared to inhibition for those with full-length GHR.
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173 :6 786GHD, healthy d3/d3 carriers present lower GHBP levels
compared with fl/fl and d3/fl genotypes (25, 26). This is,
however, unlikely to be the sole explanation for the GHR
polymorphism/GH severity interaction.
Analysis of all the GE data, based on profiling in the
baseline state, indicated that the prevailing level of GH
secretion and the GHRd3 genotype did indeed have an
impact on the genes being transcribed. The fact that
differences in GE related to growth pathways have been
demonstrated in the baseline GE shows that there are
fundamental genomic differences between patients prior
to treatment. We used causal network analysis to identify
the ‘master’ regulators of this transcription and showedwww.eje-online.orgthat these regulators differed between the four GHRd3
carriage:GHD severity groups (Fig. 4). This indicates that
these ‘master’ genetic regulators are potential biomarkers
of responsiveness to GH treatment in GHD and contribute
new knowledge to the understanding of genetic
mechanisms underlying responsiveness.
We also used the baseline GE profiles to identify genes
in those profiles that interact with GH signaling molecules
(Fig. 5). A predicted level of activity in each of these
signaling molecules was identified. This demonstrated
that GH status within each genotype and genotype within
each GH status group had different impacts on the status
of the GH signaling pathways. This provides direct in-silico
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173 :6 787evidence of how an interaction between genotype and GH
status may translate into differences in growth.
The results also show that changes in IGF1, triglycer-
ides, LDL-cholesterol, and free T4 after 1 month of r-hGH
therapy can be explained by the interaction between
GHRd3 and GHD severity (Table 3). Subjects who
responded best to therapy (i.e. severe GHD–fl/fl and mild
GHD–d3 carriers) exhibited greater increases in both IGF1
and triglyceride levels, and a greater decrease in free T4
levels. These observations are consistent with previous
findings where a GH-induced decrease in free T4 levels
(27, 28) was correlated with higher triglyceride levels
(29, 30, 31). Subjects with the fl/fl genotype and severe
GHD had a significantly greater decrease in LDL-
cholesterol levels than d3 carriers with severe GHD,
whereas there was no significant difference between fl/fl
and d3 subjects with mild GHD.
The observed relationship between change in height
and change in IGF1 further emphasizes the importance
of the GHRd3 polymorphism–GHD severity interaction.
Subjects with the fl/fl genotype and severe GHD showed a
very strong correlation between growth response and IGF1
changes. In contrast, no correlation was observed for fl/fl
subjects with mild GHD. This is intriguing and might
suggest that growth response in these latter subjects is
influenced by parameters other than IGF1, a proposal that
is supported by the transcriptomic data. These data suggest
that the GHRd3 polymorphism, shown to modulate
responsiveness to GH using in vitro cellular models (2),
may be associated with activation of different GH-signal-
ing pathways, dependent on the level of endogenous GH
present in the circulation. This also indicates that the
response to exogenous GH is driven by multiple factors
including genetic status as well as GHD severity.
In conclusion, this study shows that the interaction
between GHD severity and GHRd3 polymorphism has a
significant impact on responses to r-hGH. The controversy
in the literature on the impact of the GHRd3 poly-
morphism is likely to be due to the complexity of this
interaction and to the fact that statistical models
previously used to test for the impact of GHRd3 on growth
did not fully consider GHD severity. The fact that both
growth and the metabolic effects of GH are modulated in
the same way by the GHRd3 polymorphism–GHD severity
interaction gives added confidence to our observations.
In addition, we have demonstrated that baseline GE
profiles are influenced by GHRd3 carriage and GH status.
We suggest that our methodology provides guidance for
the analytical design of subsequent trials and that GHDseverity–GHRd3 stratification should be considered in
future pharmacogenomic studies.Supplementary data
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